Bayer's company stocks hit a
20-year low caused by a
forecasted earnings fall for 2025. The slump in the outlook, Q3 losses, and negative court decisions prompted this significant decline in their stocks. Despite the setbacks, some consider Bayer's Stocks a wise buying choice as they anticipate Bayer potentially becoming a big AI innovator. The company is also resilient, seeing an 11% soar after a notable legal win against Roundup cancer claims. However, a drop in shares was witnessed again after a U.S court decided to review the Monsanto case. The
Farm market challenges are seriously impacting Bayer's earnings, posing a fresh struggle for its CEO. Amidst these decreasing earnings, some investors recommend selling off Bayer's stock. Meanwhile, an American hedge fund places a bet on the further fall of Bayer shares. In other development,
Bayer makes plans for the expansion of its Prostate Cancer drug and closes a deal with a US biotech company NextRNA. Lastly, Bayer's shares managed to gain as activist investor Ubben takes 0.8% stake in the pharma company.
BAYER Stocks News Analytics from Fri, 22 Apr 2022 01:54:33 GMT to Fri, 24 Jan 2025 10:21:32 GMT -
Rating -5
- Innovation 2
- Information 7
- Rumor -6
